sildenafil (Rx)

Brand and Other Names:Revatio, Viagra
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet (Revatio)

  • 20mg

tablet (Viagra)

  • 25mg
  • 50mg
  • 100mg

injectable solution (Revatio)

  • 10mg/12.5mL

oral suspension (Revatio)

  • 10mg/mL (when reconstituted)
more...

Erectile Dysfunction

Viagra

50 mg PO 1 hour before sexual activity; may be increased to 100 mg or reduced to 25 mg, depending on effectiveness and tolerance; not to exceed 100 mg/day

Pulmonary Arterial Hypertension

Revatio

PO: 5 mg or 20 mg 3 times daily, administered 4-6 hours apart

IV: 2.5-mg or 10-mg bolus 3 times daily if patient is temporarily unable to take PO

Recommended PO/IV dose not to be exceeded

Adding Revatio to bosentan does not have any beneficial effect on exercise capacity

Dosing Modifications

Heaptic impairment or severe renal impairment: Use initial dose of 25 mg

Geriatric Dosing

Erectile Dysfunction

  • Viagra
  • >65 years: 25 mg PO initially 1 hour before sexual activity

Pulmonary Arterial Hypertension

  • Revatio
  • PO: 5 mg or 20 mg 3 times daily, administered 4-6 hours apart
  • IV: 2.5-mg or 10-mg bolus 3 times daily if patient is temporarily unable to take PO
  • Recommended PO/IV dose not to be exceeded
  • Adding Revatio to bosentan does not have any beneficial effect on exercise capacity
  • Clinical trials found no significant difference in response between elderly patients and younger adults; however, cautious dose selection should be considered in elderly because of greater frequency of decreased hepatic, renal, and cardiac function, as well as comorbid conditions and concomitant pharmacotherapy
  • Compared with healthy younger volunteers, healthy elderly volunteers (≥65 years) had reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively

Not to be prescribed to children (1-17 years) for pulmonary arterial hypertension (PAH); this recommendation against use is based on long-term clinical pediatric trial showing that children taking high doses had higher risk of death than children taking low doses and that low doses were not effective in improving exercise ability (see Cautions)

Next:

Interactions

Interaction Checker

and sildenafil

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Headache (7-16%)

            1-10%

            Flushing (4-10%)

            Epistaxis (8%)

            Dyspepsia (4-8%)

            Insomnia (6%)

            Erythema (5%)

            Diarrhea (4%)

            Dizziness (2%)

            Skin rash (2%)

            Postmarketing Reports

            Vaso-occlusive crisis (PAH secondary to sickle-cell anemia)

            Nonarteritic anterior ischemic optic neuropathy (NAION)

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Soluble guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension

            Coadministration with nitrates

            • Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors
            • Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates
            • A suitable time interval following PDE5 dosing for the safe administration of nitrates or nitric oxide donors has not been determined

            Cautions

            Elicits vasodilatory properties, resulting in mild and transient decreases in blood pressure

            Use with caution in patients with anatomic deformation of penis (eg, angulation, cavernosal fibrosis, or Peyronie disease), conditions potentially predisposing to priapism (eg, sickle cell anemia, multiple myeloma, or leukemia), cardiovascular disease, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, multidrug antihypertensive regimens, retinitis pigmentosa, concomitant use of CYP3A4 inhibitors

            Pulmonary vasodilators may significantly worsen cardiovascular status of patients with pulmonary veno-occlusive disease

            Patient taking alpha blocker should be stabilized before starting phosphodiesterase (PDE)-5 inhibitor, which should be initiated at lowest dose; if patient is already taking optimized dose of PDE-5 inhibitor, alpha blocker should be initated at lowest dose to avoid hypotension

            Not to be taken with other PDE-5 inhibitors

            Sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness

            Viagra: Patients should stop sildenafil and seek medical care if a sudden loss of vision occurs in 1 or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION); use with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION; patients with a ”crowded” optic disc may also be at an increased risk of NAION; advise patients to seek immediate medical attention in the event of a sudden loss of vision

            Viagra: Potential for cardiac risk with sexual activity in patients with preexisting cardiovascular disease; therefore, treatment for erectile dysfunction generally should not be instituted in men for whom sexual activity is inadvisable because of their underlying cardiovascular status

            May cause dose-related impairment of color discrimination; use caution in patients with retinitis pigmentosa

            Evaluate underlying causes of erectile dysfunction or BPH before initiating therapy

            Revatio: In small, prematurely terminated study of patients with PAH secondary to sickle-cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received sildenafil than by those randomized to placebo; effectiveness of sildenafil in PAH secondary to sickle-cell anemia has not been established; the clinical relevance to men treated for erectile dysfunction with sildenafil is not known

            Revatio: Not for use in children with PAH; increased mortality with increasing doses (hazard ratio 3.5) was observed in randomized, double-blind, placebo-controlled clinical trial of 234 children (1-17 years) with PAH who had mild-to-moderate symptoms at baseline

            Revatio: Epistaxis occurred in 13% of patients with PAH secondary to connective tissue disease (eg, scleroderma); this effect was not seen in idiopathic PAH; incidence was also higher in those receiving concomitant PO vitamin K antagonist therapy (9%) than in those not receiving such therapy (2%)

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy category: B

            Lactation: Unknown whether drug is distributed into breast milk

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Inhibits PDE-5, increasing cyclic guanosine monophosphate cGMP to allow smooth-muscle relaxation

            Absorption

            Bioavailability: 40%

            Peak plasma time: 30-120 min

            Metabolism

            Metabolized in liver by CYP3A4 and (in minor amounts) CYP2C9

            Metabolites: N-desmethyl metabolite (active; possesses 50% of sildenafil's PDE-5-inhibiting activity)

            Elimination

            Half-life: Parent drug, 3-4 hr; active metabolite, 10-70 min

            Excretion: Feces (80%), urine (13%)

            Previous
            Next:

            Administration

            IV Administration

            Revatio: Administer as an IV bolus

            Oral Administration

            Viagra

            • May take with or without food
            • Take as needed, about 1 hr before sexual activity; however, may be taken anywhere from 30 minutes to 4 hr before sexual activity
            • The maximum recommended dosing frequency is once daily

            Revatio

            • Tablets or oral suspension: Administer doses 4-6 hr apart

            Storage

            Revatio tablets or IV solution

            • Store at controlled room temperature 20-25°C (68-77°F)
            • Excursions permitted to 15-30°C (59-86°F)

            Revatio reconstituted oral suspension

            • Store <30°C (86°F) or in a refrigerator between 2-8°C (36-46°F)
            • Do not freeze
            • Discard unused oral suspension after 60 days
            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous